WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016059600) COMBINATION OF CERITINIB WITH AN EGFR INHIBITOR
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/059600    International Application No.:    PCT/IB2015/057940
Publication Date: 21.04.2016 International Filing Date: 15.10.2015
Chapter 2 Demand Filed:    16.08.2016    
IPC:
A61K 45/06 (2006.01), A61P 35/00 (2006.01), A61K 39/395 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35 4056 Basel (CH) (AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BE, BF, BG, BH, BJ, BN, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CL, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IR, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MG, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, ST, SV, SY, SZ, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW only).
BORAL, Anthony [US/US]; (US) (US only).
LI, Fang [CN/US]; (US) (US only).
LI, Nanxin [US/US]; (US) (US only).
PANTANO, Serafino [IT/CH]; (CH) (US only)
Inventors: BORAL, Anthony; (US).
LI, Fang; (US).
LI, Nanxin; (US).
PANTANO, Serafino; (CH)
Agent: HOUGHTON, Gregory; (US).
KRISTL, Jermej; Novartis Pharma AG Postfach 4002 Basel (CH)
Priority Data:
62/065,451 17.10.2014 US
62/068,175 24.10.2014 US
62/068,945 27.10.2014 US
62/118,710 20.02.2015 US
Title (EN) COMBINATION OF CERITINIB WITH AN EGFR INHIBITOR
(FR) COMBINAISON DE CERITINIB ET D'UN INHIBITEUR D'EGFR
Abstract: front page image
(EN)The present disclosure relates to a pharmaceutical composition comprising two Tyrosine Kinase Inhibitors (TKIs), namely Ceritinib and an EGFR Inhibitor. The present combination can be administered independently or separately, in a quantity which is jointly therapeutically effective for the treatment of a TKI mediated disease, such as cancer. The disclosure also provides the use of such a combination for the manufacture of a medicament; the use of such a combination as a medicine; a kit of part comprising such a combination; and a method of treatment of such a combination.
(FR)La présente invention concerne une composition pharmaceutique comprenant deux inhibiteurs de la tyrosine Kinase (TKI), à savoir le Ceritinib et un inhibiteur d'EGFR. La présente combinaison peut être administrée indépendamment ou séparément, selon une quantité qui est conjointement efficace sur le plan thérapeutique pour traiter une maladie médiée par des TKI, telle que le cancer. L'invention concerne également l'utilisation d'une telle combinaison pour fabriquer un médicament; l'utilisation d'une telle combinaison en tant que médicament; un kit d'éléments comprenant une telle combinaison; et une méthode de traitement utilisant une telle combinaison.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)